Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERITAC-3: vepdegestrant + palbociclib versus letrozole + palbociclib in first-line ER-positive/HER2-negative advanced breast cancer
CTR20232668Phase 3Active
- Sponsor
- Pfizer
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vepdegestrant, palbociclib, letrozole in breast cancer, sponsored by Pfizer. Started Sep 2023; status: active.
02
Drugs
vepdegestrantpalbociclibletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20232668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232668.